Multiple Myeloma—Effect of Induction Therapy on Transplant Outcomes
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 21 (2) , 80-90.e5
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trialThe Lancet, 2017
- Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple MyelomaTransplantation and Cellular Therapy, 2017
- VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trialBlood, 2016
- Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell MobilizationTransplantation and Cellular Therapy, 2013
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM studyBlood, 2012
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 TrialJournal of Clinical Oncology, 2012
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 studyThe Lancet, 2010
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III TrialJournal of Clinical Oncology, 2010
- Poor Mobilization of Hematopoietic Stem Cells—Definitions, Incidence, Risk Factors, and Impact on Outcome of Autologous TransplantationTransplantation and Cellular Therapy, 2010
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998